GUFICBIO Intraday Analysis...

GUFICBIO Share Price

Open 67.00 Change Price %
High 71.00 1 Day 2.20 3.28
Low 66.25 1 Week 2.85 4.29
Close 69.30 1 Month 1.90 2.82
Volume 578290 1 Year 29.50 74.12
52 Week High 74.00
52 Week Low 32.10
GUFICBIO Important Levels
Resistance 2 73.70
Resistance 1 71.89
Pivot 68.85
Support 1 66.71
Support 2 64.90
NSE INDIA Most Active Stocks
SUZLON 20.85 0.24%
GMRINFRA 17.15 -3.92%
JPASSOCIAT 13.10 0.77%
ADANIENT 118.55 -20.94%
IBREALEST 154.05 -2.59%
IDFCBANK 61.20 3.03%
SOUTHBANK 24.15 -3.21%
PNB 167.15 3.76%
UNITECH 5.70 -2.56%
JPINFRATEC 13.85 6.95%
NSE INDIA Top Gainers Stocks
KSERASERA 0.20 33.33%
VSSL 124.80 20.00%
ATNINTER 0.30 20.00%
RKDL 13.65 19.74%
WELINV 127.75 18.29%
TCIDEVELOP 533.00 17.56%
HBSTOCK 25.65 16.06%
HUBTOWN 146.30 12.50%
SYNCOM 6.75 12.50%
NAKODA 0.45 12.50%
NSE INDIA Top Losers Stocks
BLS 170.40 -89.85%
ADANIENT 118.55 -20.94%
SHILPI 165.90 -19.99%
AUSTRAL 0.25 -16.67%
MAHASTEEL 85.25 -9.74%
ZENSARTECH 838.65 -8.73%
KAMATHOTEL 45.05 -8.53%
ZENITHBIR 0.55 -8.33%
NICCO 0.55 -8.33%
ROLLT 9.75 -8.02%

Gufic Biosciences Limited (NSE: GUFICBIO)

GUFICBIO Technical Analysis 5
As on 26th Apr 2017 GUFICBIO Share Price closed @ 69.30 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 49.48 & Strong Buy for SHORT-TERM with Stoploss of 62.39 we also expect STOCK to react on Following IMPORTANT LEVELS.
GUFICBIO Target for April
1st Target up-side 76.4
2nd Target up-side 83.41
3rd Target up-side 90.42
1st Target down-side 56.4
2nd Target down-side 49.39
3rd Target down-side 42.38
GUFICBIO Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 59.19 Sideways
MFI (14) MFI is 63.62 Sideways
CCI (20) CCI is 16.96 Sideways
WILLIAM %R (14) William %R is -56.97 Sideways
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Short Sell 72.34
10 Day Avg Volume Traded 172.55 % More then 10 Day Average Volume
GUFICBIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website
Kamala Bhavan II
Shop - 37, First Floor
Mumbai, 400069
GUFICBIO Latest News
Limited Review for Dec 31, 2014   Hindu Business Line   - 03rd Mar 15
Proposed Bank Strikes   Hindu Business Line   - 17th Feb 15
Gufic Bio standalone Dec '14 sales at Rs 34.34 crore   - 17th Feb 15
BSE Breaches 25.8k Mark; Metals, Goods, Auto and Power Stocks Fall   International Business Times, India Edition   - 04th Jul 14
NPPA sends notices in 89 cases of overcharging to recover   - 22nd Apr 14
Gufic BioSciences Ltd Recommends Dividend   Reuters Key Development   - 31st May 13
Cops hunt for fake drug maker   Times of India   - 24th Feb 09
Interactive Technical Analysis Chart Gufic Biosciences Limited ( GUFICBIO NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Gufic Biosciences Limited
GUFICBIO Business Profile
Gufic Biosciences (GUFICBIO) is a pharmaceuticals and biosciences company. Incorporated in 1984 as Central Finance, the company got its current name on Jun. 05, 2000. The company operates in the segments of pharma, healthcare, bio-technology, seeds, herbal, R&D, and bulk drugs. The company provides pharma medicines for diarrhoea (Ridol), episiotomy (Zad-g), anemia (Optifer), infections (Lotril), inflammation (Valsafe)...etc. The healthcare segment provides consumer and personal hygiene products like roll-ons for cold and sanitary napkins like Shapers. The biotechnology segment produces high-yielding and elite planting material of medicinal and other herbal plants using tissue culture techniques. The tissue culture facility produces five million plants per annum. The company has two green houses of 800 sq. m. Production includes banana, potato, sugarcane, date palm, jatropha, and bixa (source of natural food color). It brings out hybrid varieties of major vegetable seeds like tomato, chilli, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd, bitter gourd, ridge gourd, brinjal, cucumber and watermelon. The company provides herbal and ayurvedic medicines for muscular pains (Sallaki); menstrual excesses (Eugynin); hyperacidity, gastritis, and chronic fungal dyspepsia (Zulcer), aches and pains (Rumastal-forte), liver problems (Livpar), constipation (Laxive), and cough (Kofend Syrup). Bulk drugs include anesthetics (lidocaine), antifungals (econazole, miconazole, ketokonazole), antiielmintic (mebendazole, polymorph), cathartic (castor oil), and food colors. The company has its facilities in Vile Parle, Mumbai and a plant in Navsari, Gujarat. The R&D Centre is a state-of-the-art research laboratory and provides total product development by developing new pharmaceutical products, new drug delivery systems, and new platform technologies. The functional areas are formulation development, analytical development, packaging development and documentation. The current market capitalization stands at Rs 44.48 crore. The company has reported a standalone sales of Rs 29.03 crore and a Net Profit of Rs 1.15 crore for the quarter ended September 2013. The company management includes Jayesh P Choksi - Chairman & Managing Director, Pranav J Choksi - Executive & Wholetime Director, M G Dhapalapur - Executive & Wholetime Director, Sharat S Gandhi - Ind. Non-Executive Director, Ashok M Tarale - Ind. Non-Executive Director, Khantilal N Sanghavi - Ind. Non-Executive Director, Pankaj J Gandhi - Additional Director, Jagdish D Shah - Additional Director. The Registered office is at Shop - 37, First Floor, Kamala Bhavan II, Swami Nityanand Road, Mumbai, Maharashtra - 400069.